RESULTS
Of the 61 patients who were admitted to our clinic for Peyronie’s disease, 48 patients who met the inclusion criteria were included in the study. All patients completed the 8-week treatment protocol. No patients were excluded from the study because no serious side effects or worsening of symptoms were observed during the protocol. The mean age was 61.1 (43-78). The average time from the onset of complaints was 3.4 months (0-9). Curvature was dorsal in 19 (39.6%) patients, ventral in 5 (10.4%) patients, lateral in 12 (25%) patients, and dorsolateral in 12 (25%) patients. The average plaque size before treatment was 13.6 mm (7.1-16.8), and after treatment, this value decreased to 10.8 mm (4.3-14.6) (p = 0.025) (Figure 1). In 35 (72.9%) of the 48 patients, a decrease in plaque size was seen after treatment. Plaque size did not increase in for any of the patients after treatment. The mean curvature angle was 55.7 degrees (35-85) before treatment, whereas this value decreased to 52.5 degrees (33-85) after treatment. In 8 (16.7%) of the 48 patients, the curvature angle was reduced, but this decrease was not statistically significant (p:0.07) (Figure 2). In five patients (10.4%), curvature angle was increased. This increase was no more than 10 degrees. The changes in plaque size and curvature angle did not show any statistically significant difference with respect to curvature direction (p = 0.145). No local or systemic side effects or complications were observed during or after drug administration, excluding pain resulting from the injection of the drug.
The average IIEF-5 score before treatment was 18.1 (10-25). This score increased to 20.2 (10-25) after treatment. However, this rise was not statistically significant (p = 0.069). The PDQS score was 12.3 (4-18) on average, and this value decreased significantly to 8.9 (0-14) after treatment (p = 0.001). The PDQP score average was 19.1 (12-26) before treatment and significantly decreased to 9.6 (0-21) after treatment (p < 0.001). Finally, the PDQB score decreased significantly after treatment, as did the other scores. Before treatment, this value was 6.2 (4-12), and after treatment, it was 4.4 (2-10) (p = 0.045) (Figure 3).